Generate Biomedicines (NASDAQ:GENB) Trading 5.9% Higher – Still a Buy?

Generate Biomedicines Inc (NASDAQ:GENB)’s share price traded up 5.9% during mid-day trading on Wednesday . The company traded as high as $12.70 and last traded at $12.68. 466,795 shares traded hands during mid-day trading, a decline of 14% from the average session volume of 541,836 shares. The stock had previously closed at $11.97.

Analyst Upgrades and Downgrades

A number of research analysts have weighed in on the stock. Cantor Fitzgerald assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating on the stock. Wall Street Zen cut shares of Generate Biomedicines from a “hold” rating to a “sell” rating in a research report on Saturday, May 9th. Piper Sandler assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set an “overweight” rating and a $24.00 price target on the stock. HC Wainwright lifted their price target on shares of Generate Biomedicines from $16.00 to $25.00 and gave the company a “buy” rating in a research report on Friday, May 8th. Finally, The Goldman Sachs Group assumed coverage on shares of Generate Biomedicines in a research report on Tuesday, March 24th. They set a “buy” rating and a $26.00 price target on the stock. Six equities research analysts have rated the stock with a Buy rating and one has given a Hold rating to the company. Based on data from MarketBeat, Generate Biomedicines currently has a consensus rating of “Moderate Buy” and an average target price of $25.40.

Generate Biomedicines Trading Up 13.9%

The company has a 50-day simple moving average of $13.17.

Generate Biomedicines (NASDAQ:GENB) last posted its earnings results on Thursday, May 7th. The company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.